REFERENCES

1. Hawkes N. Cancer survival data emphasise importance of early diagnosis. BMJ 2019;364:l408.

2. Hosseini H, Obradovic MMS, Hoffmann M, Harper KL, Sosa MS, et al. Early dissemination seeds metastasis in breast cancer. Nature 2016;540:552-8.

3. Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med 2013;19:1450-64.

4. Peng JM, Bera R, Chiou CY, Yu MC, Chen TC, et al. Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice. Hepatology 2018;67:2226-43.

5. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013;19:1423-37.

6. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.

7. Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature 2016;529:298-306.

8. Fischer KR, Durrans A, Lee S, Sheng J, Li F, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.

9. Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun 2018;9:2897.

10. Yin Z, Pascual C, Klionsky D. Autophagy: machinery and regulation. Microb Cell 2016;3:588-96.

11. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 2011;13:132-41.

12. Parzych KR, Klionsky DJ. An Overview of Autophagy: Morphology, Mechanism, and Regulation. Antioxid Redox Signal 2014;20:460-73.

13. Feng Y, He D, Yao Z, Klionsky DJ. The machinery of macroautophagy 24 The machinery of macroautophagy. Cell Res 2014;24:24-41.

14. Lee YK, Lee JA. Role of the mammalian ATG8/LC3 family in autophagy: Differential and compensatory roles in the spatiotemporal regulation of autophagy. BMB Rep 2016;49:424-30.

15. Nazio F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications. Cell Death Differ 2019;26:690-702.

16. Gugnoni M, Sancisi V, Manzotti G, Gandolfi G, Ciarrocchi A. Autophagy and epithelial-mesenchymal transition: an intricate interplay in cancer. Cell Death Dis 2016;7:e2520.

17. Galavotti S, Bartesaghi S, Faccenda D, Shaked-Rabi M, Sanzone S, et al. The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene 2013;32:699-712.

18. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-26.

19. Meredith JE, Fazeli B, Schwartz MA, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-61.

20. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of Autophagy during Extracellular Matrix Detachment Promotes Cell Survival. Mol Biol Cell 2008;19:797-806.

21. Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: Another double-edged sword. Curr Opin Cell Biol 2010;22:241-5.

22. Peng YF, Shi YH, Ding ZB, Ke AW, Gu CY, et al. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy 2013;9:2056-68.

23. Mowers EE, Sharifi MN, Macleod KF. Autophagy in cancer metastasis. Oncogene 2017;36:1619-30.

24. Chen HT, Liu H, Mao MJ, Tan Y, Mo XQ, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer 2019;18:101.

25. Banyard J, Bielenberg DR. The role of EMT and MET in cancer dissemination. Connect Tissue Res 2015;56:403-13.

26. Barnard RA, Regan DP, Hansen RJ, Maycotte P, Thorburn A, et al. Autophagy Inhibition Delays Early but Not Late-Stage Metastatic Disease. J Pharmacol Exp Ther 2016;358:282-93.

27. Paul P, Chakraborty A, Sarkar D, Langthasa M, Rahman M, et al. Interplay between miRNAs and human diseases. J Cell Physiol 2018;233:2007-18.

28. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 2018;9:402.

29. Di Leva G, Garofalo M, Croce CM. MicroRNAs in Cancer. Annu Rev Pathol 2014;9:287-314.

30. Wang W, Liu Y, Guo J, He H, Mi X, et al. miR-100 maintains phenotype of tumor-associated macrophages by targeting mTOR to promote tumor metastasis via Stat5a/IL-1ra pathway in mouse breast cancer. Oncogenesis 2018;7:97.

31. Ottaviani S, Stebbing J, Frampton AE, Zagorac S, Krell J, et al. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications 2018;9:10.

32. Zhang F, Wang J, Chu J, Yang C, Xiao H, et al. MicroRNA-146a Induced by Hypoxia Promotes Chondrocyte Autophagy through Bcl-2. Cell Physiol Biochem 2015;37:1442-53.

33. Yang L, Zhao G, Wang F, Li C, Wang X. Hypoxia-Regulated miR-146a Targets Cell Adhesion Molecule 2 to Promote Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma. Cell Physiol Biochem 2018;49:920-931.

34. Zhou W, Thiery JP. Loss of Git2 induces epithelial-mesenchymal transition by miR146a-Cnot6L-controlled expression of Zeb1. J Cell Sci 2013;126:2740-6.

35. An Y, Zhang Z, Shang Y, Jiang X, Dong J, et al. miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis 2015;6:e1766.

36. Cao J, Liu J, Long J, Fu J, Huang L, et al. microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2. Biomed Pharmacother 2017;89:642-50.

37. Pan B, Chen Y, Song H, Xu Y, Wang R, et al. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget 2015;6:317-31.

38. Kang H, Rho JG, Kim C, Tak H, Lee H, et al. The MIR-24-3p/p130Cas: A novel axis regulating the migration and invasion of cancer cells. Sci Rep 2017;7:44847.

39. Jin F, Wang Y, Li M, Zhu Y, Liang H, et al. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis 2018;8:e2540.

40. Chang L, Li K, Guo T. miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC. Clin Transl Oncol 2017;19:695-703.

41. Yang X, Bai F, Xu Y, Chen Y, Chen L. Intensified Beclin-1 Mediated by Low Expression of Mir-30a-5p Promotes Chemoresistance in Human Small Cell Lung Cancer. Cell Physiol Biochem 2017;43:1126-39.

42. Wei W, Yang Y, Cai J, Cui K, Li RX, et al. MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3. Cell Physiol Biochem 2016;39:1165-76.

43. Liu L, Ren W, Chen K. MiR-34a promotes apoptosis and inhibits autophagy by targeting HMGB1 in acute myeloid leukemia cells. Cell Physiol Biochem 2017;41:1981-92.

44. Pang J, Xiong H, Lin P, Lai L, Yang H, et al. Activation of miR-34a impairs autophagic flux and promotes cochlear cell death via repressing ATG9A: implications for age-related hearing loss. Cell Death Dis 2017;8:e3079.

45. Zhang X, Ai F, Li X, Tian L, Wang X, et al. MicroRNA-34a suppresses colorectal cancer metastasis by regulating notch signaling. Oncol Lett 2017;14:2325-33.

46. Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, et al. Cell Cycle miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011;10:4256-71.

47. Kim JK, Yuk JM, Kim SY, Kim TS, Jin HS, et al. MicroRNA-125a Inhibits Autophagy Activation and Antimicrobial Responses during Mycobacterial Infection. J Immunol 2015;194:355-65.

48. Fan Z, Cui H, Xu X, Lin Z, Zhang X, et al. MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3. Oncotarget 2015;6:25266-80.

49. Yang Y, Liu Y, Xue J, Yang Z, Shi Y, et al. MicroRNA-141 Targets Sirt1 and Inhibits Autophagy to Reduce HBV Replication. Cell Physiol Biochem 2017;41:310-22.

50. Huang S, Wa Q, Pan J, Peng X, Ren D, et al. Downregulation of miR-141-3p promotes bone metastasis via activating NF-κB signaling in prostate cancer. J Exp Clin Cancer Res 2017;36:173.

51. Liu C, Liu R, Zhang D, Deng Q, Liu B, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun 2017;8:14270.

52. Wei J, Ma Z, Li Y, Zhao B, Wang D, et al. MiR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. Mol Med Rep 2015;11:571-6.

53. Lei C, Du F, Sun L, Li T, Li T, et al. MIR-143 & MIR-145 inhibit gastric cancer cell migration & metastasis by suppressing MYO6. Cell Death Dis 2017;8:e3101.

54. Li B, Wu X, Chen H, Zhuang C, Zhang Z, et al. MiR199a-5p inhibits hepatic insulin sensitivity via suppression of ATG14-mediated autophagy article. Cell Death Dis 2018;9:405.

55. Aranda JF, Rathjen S, Johannes L, Fernández-Hernando C, Francisco Aranda J. MiR-199a-5p attenuates retrograde transport and protects against toxin-2 induced inhibition of protein biosynthesis. Mol Cell Biol 2018;38:e00548-17.

56. Zhan Y, Zheng N, Teng F, Bao L, Liu F, et al. MiR-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1. Oncotarget 2017;8:67169-80.

57. Pan B, Feng B, Chen Y, Huang G, Wang R, et al. MiR-200b regulates autophagy associated with chemoresistance in human lung adenocarcinoma. Oncotarget LLC 2015;6:32805-20.

58. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.

59. Lai HH, Li JN, Wang MY, Huang HY, Croce CM, et al. HIF-1α promotes autophagic proteolysis of dicer and enhances tumor metastasis. J Clin Invest 2018;128:625-43.

60. Gao AM, Zhang XY, Hu JN, Ke ZP. Apigenin sensitizes hepatocellular carcinoma cells to doxorubic through regulating miR-520b/ATG7 axis. Chem Biol Interact 2018;280:45-50.

61. Lu YC, Cheng AJ, Lee LY, You GR, Li YL, et al. MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44. Sci Rep 2017;7:2042.

62. Liu X, Hong Q, Wang Z, Yu Y, Zou X, et al. MiR-21 inhibits autophagy by targeting Rab11a in renal ischemia/reperfusion. Experimental Cell Res 2015;338:64-9.

63. Wang WJ, Yang W, Ouyang ZH, Xue JB, Li XL, et al. MiR-21 promotes ECM degradation through inhibiting autophagy via the PTEN/akt/mTOR signaling pathway in human degenerated NP cells. Biomed Pharmacother 2018;99:725-34.

64. Liu ZL, Wang H, Liu J, Wang ZX. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 2013;372:35-45.

65. Xu Y, Yang J, Li F, Lian G, Ouyang M. MiR-29a inhibited intestinal epithelial cells autophagy partly by decreasing ATG9A in ulcerative colitis. Anti-Cancer Drug 2018;29:652-9.

66. Tang W, Zhu Y, Gao J, Fu J, Liu C, et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br J Cancer 2013;110:450-8.

67. Li N, Miao Y, Shan Y, Liu B, Li Y, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death Dis 2017;8:e2796.

68. Lu C, Chen J, Xu HG, Zhou X, He Q, et al. MIR106B and MIR93 prevent removal of bacteria from epithelial cells by disrupting ATG16L1-mediated autophagy. Gastroenterology 2014;146:188-99.

69. Chu S, Liu G, Xia P, Chen G, Shi F, et al. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. Oncol Rep 2017;38:2401-7.

70. Hu JL, He GY, Lan XL, Zeng ZC, Guan J, et al. Inhibition of ATG12-mediated autophagy by miR-214 enhances radiosensitivity in colorectal cancer. Oncogenesis 2018;7:16.

71. Liu J, Li D, Dang L, Liang C, Guo B, et al. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer. Sci Rep 2017;7:40487.

72. Xu J, Su Y, Xu A, Fan F, Mu S, et al. miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma. Mol Ther 2019;27:559-70.

73. Liang YK, Lin HY, Dou XW, Chen M, Wei XL, et al. MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines. NPJ Breast Cancer 2018;4:20.

74. Dubinsky AN, Ghosh Dastidar S, Hsu CL, Zahra R, Djakovic S, et al. Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy. Cell Metab 2014;20:626-38.

75. Ling R, Zhou Y, Zhou L, Dai D, Wu D, et al. Lin28/microRNA-let-7a promotes metastasis under circumstances of hyperactive Wnt signaling in esophageal squamous cell carcinoma. Mol Med Rep 2018;17:5265-71.

76. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-62.

77. Kong X, Li G, Yuan Y, He Y, Wu X. MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. PLoS One 2012;7:e41523.

78. Janaki Ramaiah M, Lavanya A, Honarpisheh M, Zarea M, Bhadra U, et al. MiR-15/16 complex targets p70S6 kinase1 and controls cell proliferation in MDA-MB-231 breast cancer cells. Gene 2014;552:255-64.

79. Zhang H, Yang K, Ren T, Huang Y, Tang X, et al. MiR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3 article. Cell Death Dis 2018;9:680.

80. Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, et al. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol 2014;87:579-97.

81. Zhuo Z, Yu H, Zhuo Z, Yu H, Zhuo Z, et al. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. Oncotarget 2017;8:28042-51.

82. Gulei D, Magdo L, Jurj A, Raduly L, Cojocneanu-Petric R, et al. The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. Cell Death Dis 2018;9:66.

83. Chen D, Sun Y, Yuan Y, Han Z, Zhang P, et al. miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion. PLoS Genet 2014;10:e1004177.

84. Wang C, Zhang W, Zhang L, Chen X, Liu F, et al. miR-146a-5p mediates epithelial-mesenchymal transition of oesophageal squamous cell carcinoma via targeting Notch2. Brit J Cancer 2016;115:1548-54.

85. Zhang MX, Zhang J, Zhang H, Tang H. MiR-24-3p suppresses malignant behavior of lacrimal adenoid cystic carcinoma by targeting PRKCH to regulate p53/p21 pathway. PLoS ONE 2016;11:e0158433.

86. Chao CC, Wu PH, Huang HC, Chung HY, Chou YC, et al. Downregulation of miR-199a/b-5p is associated with GCNT2 induction upon epithelial-mesenchymal transition in colon cancer. FEBS Lett 2017;591:1902-17.

87. Bornachea O, Santos M, Martínez-Cruz AB, García-Escudero R, Dueñas M, et al. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep 2012;2:434.

88. Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun 2018;9:1944.

89. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643-53.

90. Keklikoglou I, Cianciaruso C, Guc E, Squadrito ML, Spring LM, et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol 2019;21:190-202.

91. Schoenherr C, Byron A, Sandilands E, Paliashvili K, Baillie GS, et al. Ambra1 spatially regulates Src activity and Src/FAK-mediated cancer cell invasion via trafficking networks. Elife 2017;6:e23172.

92. Sharifi MN, Mowers EE, Drake LE, Collier C, Chen H, et al. Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Rep 2016;15:1660-72.

93. Anderson RL, Balasas T, Callaghan J, Coombes RC, Evans J, et al. A framework for the development of effective anti-metastatic agents. Nat Rev Clin Oncol 2019;16:185-204.

94. Huggett B, Paisner K. The commercial tipping point. Nat Biotechnol 2017;35:708-9.

95. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017;16:203-22.

96. van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 2017;18:1386-96.

97. Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 2017;35:180-8.

98. Vo DD, Staedel C, Zehnacker L, Benhida R, Darfeuille F, et al. Targeting the Production of Oncogenic MicroRNAs with Multimodal Synthetic Small Molecules. ACS Chem Biol 2014;9:711-21.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/